But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss ...

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

Novo Nordisk (NVO) stock gains as the FDA approves the company's Wegovy pill, as Eli Lilly (LLY) awaits FDA review for its ...

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...

Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.

Novo Nordisk's weight-loss pill, Wegovy, has been approved by the FDA, giving the company a competitive edge in the market ...

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug.

Monday’s approval gives Novo Nordisk a win against GLP-1 competitor Eli Lilly, which manufactures a weight loss injectable ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.